Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose of Debio 0932 when
administered orally, every-other-day or daily during the first 30 days, in patients with
solid tumours or lymphoma.